Our AI
Privacy
15 minute meeting
To explore personalized outperforming therapies.
Our AI
Privacy
15 minute meeting
To explore personalized outperforming therapies.


RARE DISEASE
Acquired hemophilia A
Acquired hemophilia A
Acquired hemophilia A
Synonyms: AHA, Acquired F8 deficiency, Acquired factor VIII deficiency
Synonyms: AHA, Acquired F8 deficiency, Acquired factor VIII deficiency
Synonyms: AHA, Acquired F8 deficiency, Acquired factor VIII deficiency
Drug discovery
896
papers
On emerging therapies
Rare hematologic diseases
Acquired hemophilia A
Overview
Acquired Hemophilia A (AHA) is a rare bleeding disorder caused by autoantibodies against factor VIII, leading to impaired coagulation. It presents with spontaneous mucocutaneous or soft-tissue bleeding, often in older adults without prior bleeding history. Diagnosis requires confirmation of factor VIII deficiency and inhibitor detection via Bethesda assay. Management prioritizes bleeding control with bypassing agents (e.g., recombinant FVIIa, aPCC) or recombinant porcine FVIII, followed by immunosuppressive therapy (corticosteroids ± cyclophosphamide/rituximab) for inhibitor eradication [1][2][3][6][12].
Burden
Mortality: Up to 21%, with bleeding complications (3-9%) and immunosuppression-related infections (14%) as leading causes [6][9].
Delayed diagnosis increases morbidity; treatment costs are substantial (e.g., $6M per hospitalization for rpFVIII) [6][14].
Comorbidities (e.g., cardiovascular disease) complicate management in elderly patients [6][12].
Therapies
Hemostasis: Bypassing agents (rFVIIa, aPCC) or recombinant porcine FVIII for acute bleeding; emicizumab considered in refractory cases or contraindications to traditional therapies [1][3][6][12].
Immunosuppression: First-line: corticosteroids ± cyclophosphamide; second-line: rituximab. Remission achieved in ~79% within months [1][3][6][8].
Categories: rare hematological diseases
Research Papers
896 drug discovery papers about Acquired hemophilia A, with 3 first-in-class emerging drug candidates forecasted to outperform the average preclinical success rate. Recent publications:
896 drug discovery papers about Acquired hemophilia A, with 3 first-in-class emerging drug candidates forecasted to outperform the average preclinical success rate. Recent publications:
categories:
Small molecules
small molecules
2026-07-11 | Prepartum Acquired Hemophilia A: Managing a Double Challenge for Mother and Child.
Acquired haemophilia A (AHA) during pregnancy is exceptionally rare and poses significant risks to both mother and fetus, including maternal hemorrhage and neonatal bleeding due to transplacental transfer of factor VIII (FVIII) inhibitors. We report four cases of antenatally diagnosed AHA to provide insights into management and outcomes. All patients received corticosteroids during pregnancy, with individualized peripartum haemostatic strategies using bypassing agents when indicated. Transplacental FVIII inhibitor transfer occurred in three neonates, leading to transient low FVIII levels; only one mild bleeding event was observed, and all infants achieved spontaneous remission within weeks. Postpartum escalation of immunosuppressive therapy, including rituximab, was required in selected mothers to achieve remission. Our series highlights the critical importance of prepartum diagnosis, allowing optimized maternal haemostatic management, avoidance of traumatic delivery, and structured neonatal surveillance to prevent severe bleeding complications.
2026-02-02 | Direct oral anticoagulant interference and removal in the factor VIII inhibitor assay.
Direct oral anticoagulants (DOACs) interfere with clot-based assays, including factor (F)VIII testing and the Nijmegen-Bethesda assay, potentially leading to false-positive results for FVIII inhibitors. Misinterpretation of these results carries serious clinical consequences. Activated charcoal-based products, such as DOAC Remove, may restore assay accuracy, but data supporting their use in FVIII inhibitor assays are limited. In this study, we aim to determine DOAC interference in FVIII inhibitor testing and evaluate effectivity of DOAC removal to restore assay reliability. Normal pooled plasma was spiked with therapeutic and supratherapeutic concentrations of apixaban, edoxaban, rivaroxaban, and dabigatran. Plasma pools from persons with acquired hemophilia A were spiked with DOACs and retested with and without DOAC removal treatment to evaluate workflow performance. FVIII inhibitor activity was measured with and without activated charcoal-based DOAC removal to establish DOAC interference and removal efficacy. Spiking experiments with DOACs caused concentration-dependent false-positive FVIII inhibitor results (>0.6 Nijmegen Bethesda Units/mL), with dabigatran showing the strongest interference and apixaban the weakest. DOAC removal substantially reduced or eliminated interference across all drugs. Post-removal FVIII inhibitor values closely matched baseline concentrations in both spiked normal pooled plasma and pooled patient plasma, with most results within ±20% of the assay variability. DOACs significantly interfere with FVIII inhibitor assays, potentially causing clinically significant false-positive results. Activated charcoal-based DOAC removal treatment provides a practical solution to restore assay reliability. These findings support the integration of DOAC removal into anti-FVIII testing protocols for patients on anticoagulant therapy.
2026-02-01 | Diagnostic Challenges in Acquired Hemophilia A with Concomitant Oral Anticoagulant Use: A Case Series Analysis
Introduction Acquired hemophilia A (AHA) is an uncommon autoimmune bleeding disorder caused by inhibitory autoantibodies directed against coagulation factor VIII (FVIII). Laboratory monitoring of AHA involves serial inhibitor assays to assess treatment response and detect relapse [ 1 ]. The Bethesda assay and its Nijmegen-modified variant quantify residual FVIII activity after incubation of normal plasma with patient plasma, using either a one-stage clotting assay (OSCA) or a chromogenic substrate assay (CSA) [ 2 ]. Both assay formats, however, are susceptible to analytical interference by direct oral anticoagulants (DOACs). In particular, undetected direct factor Xa inhibitors (DFXaIs) may lead to falsely elevated Bethesda titers, potentially misinterpreted as persistent FVIII inhibitors despite clinical remission [ 3 ]. Method Two elderly female patients, aged 86 and 87 years, both with previously treated AHA and confirmed eradication of FVIII autoantibodies, presented during routine follow-up with borderline positive Nijmegen-modified Bethesda assay results (0.7 and 0.8 BU/mL; reference<0.5 BU/mL). Neither patient was under immunosuppressive therapy. Both received apixaban 2.5 mg twice daily—one for secondary prevention after cardioembolic stroke, the other for non-valvular atrial fibrillation. Laboratory testing revealed normal haemostatic screening tests. Liver function tests were within normal limits. Estimated glomerular filtration rate (eGFR) was consistent with moderate-to-severe chronic kidney disease. Haemostatic monitoring included FVIII activity measurement using both OSCA and CSA methods, von Willebrand factor (vWF) activity and antigen, anti-FVIII antibody detection by ELISA, and FVIII inhibitor quantification using the Nijmegen-modified Bethesda assay after heat inactivation. To evaluate possible interference from DOACs, plasma samples were pretreated with DOAC-Remove® and the Nijmegen-modified Bethesda assay was repeated. Results After pretreatment with DOAC-Remove®, FVIII inhibitors were no longer detectable ([ Fig. 1 ]). Apixaban concentrations dropped below the analytical detection limit (<20 ng/mL), confirming effective DOAC removal. Positive control samples containing low-titer FVIII inhibitors demonstrated that DOAC-Remove® treatment did not inactivate FVIII autoantibodies, confirming assay validity. Fig. 1 Laboratory results in patients with AHA before and after DOAC-Remove® Conclusion Accurate laboratory assessment is essential for the diagnosis and follow-up of AHA. False-positive FVIII inhibitor results due to interference from DFXaIs can lead to misinterpretation of disease persistence and inappropriate clinical management. Anti-FVIII ELISA testing may serve as a complementary approach when DFXaI interference is suspected, but its limited specificity must be considered. Pretreatment of plasma samples with activated charcoal-based adsorbents such as DOAC-Remove® or DOAC-Stop® offers a simple and effective method to eliminate DFXaI interference in Nijmegen-modified Bethesda assays, thereby enhancing diagnostic reliability in AHA monitoring. Publication History Article published online: 17 February 2026 © 2026. Thieme. All rights reserved. Georg Thieme Verlag KG Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany
2025-11-07 | Acquired Factor VIII (FVIII) Deficiency: A Case of Idiopathic Hemorrhage.
We report the case of a 34-year-old female with no prior medical history or known bleeding disorders who presented with a large, spontaneous right arm hematoma developing gradually over 10 days, without preceding trauma. She also had multiple ecchymoses and a history of a right calf hematoma three months earlier, initially misdiagnosed and managed as deep venous thrombosis and later as muscle cramp. Laboratory evaluation revealed anemia (hemoglobin: 9.9 g/dL) and a markedly prolonged activated partial thromboplastin time (aPTT) that failed to correct with mixing studies. Factor VIII activity was severely reduced at 4%, with an inhibitor titer of 3.1 Bethesda units, confirming acquired hemophilia A. Imaging demonstrated an intramuscular hematoma within the biceps. The patient was treated with high-dose intravenous methylprednisolone for three days, a single dose of cyclophosphamide, and transitioned to oral prednisolone and azathioprine. Within 24 hours, her aPTT improved to near-normal, and at one-month follow-up, she demonstrated complete resolution of symptoms, normalized FVIII activity, and no recurrence. This case underscores the importance of prompt recognition and combined laboratory, imaging, and clinical assessment in diagnosing acquired hemophilia, particularly in atypical presentations without mucocutaneous bleeding. Early targeted immunosuppressive therapy can result in rapid inhibitor eradication and favorable outcomes.
2025-08-26 | P80 | Early rituximab in acquired haemophilia A: two cases report
Background: Acquired hemophilia A (AHA) is a rare event caused by the development of autoantibodies against factor VIII protein (FVIII). Guidelines recommend rituximab or cytotoxic agents as second-line therapy after 3-4 weeks of corticosteroids to eradicate FVIII inhibitor. We present two case reports of early rituximab use in AHA patients.Case 1: A man with myelomonocytic leukemia presented with widespread hematomas. Lab results showed anemia, prolonged aPTT, FVIII activity 0%, and an inhibitor level of 1.9 BU. Initial treatment with Methylprednisolone, APCC and rVIIa had limited response. Early rituximab therapy (375 mg/m2 weekly for 4 weeks) led to progressive hematoma resolution and eliminated the need for transfusions. After 4 weeks, aPTT was 35s, FVIII activity increased to 62%, and the inhibitor level dropped to 0.4 BU. Case 2: A man with metastatic gastric cancer in chemotherapy presented with left gluteal and abdominal swelling, severe anemia, and prolonged aPTT, reduced FVIII levels and the presence of FVIII inhibitor. CT scan showed the presence of muscular hematomas requiring embolization of the left gluteal and superficial left circumflex iliac arteries. Methylprednisolone and rVIIa were initiated with stability for two weeks. New hematomas prompted rituximab therapy, resulting in hematoma resolution, clinical improvement, normalizing aPTT, FVIII activity with FVIII inhibitor complete eradication.Conclusions: Early rituximab use, contrary to guidelines, effectively restored FVIII levels, reduced inhibitors, and resolved hemorrhagic symptoms in AHA patients.
proteins
2026-07-17 | Acquired hemophilia a induced by clopidogrel
Introduction . Dual antiplatelet therapy (DATT) with aspirin and a platelet P2Y12 receptor inhibitor is one of the main components of treatment and secondary prevention in patients undergoing percutaneous coronary intervention in acute myocardial infarction. Among the side effects of DATT are hemorrhagic complications caused by the antiplatelet effect of the drugs. Less is known about hemorrhagic complications caused by coagulation disorders when taking clopidogrel. Aim : to present a clinical case of acquired hemophilia A, which occurred in a patient as a result of taking clopidogrel. Main findings . A 68-year-old patient received clopidogrel as part of DATT after percutaneous coronary intervention. One month later, he developed a pronounced hemorrhagic syndrome caused by the appearance of antibodies to coagulation factor VIII (FVIII:C 1.5 %, factor VIII inhibitor 61 BU). The elimination of clopidogrel, hemostatic therapy with eptacog alpha (activated) and immunosuppressive therapy with prednisone, cyclophosphamide and rituximab allowed not only to stop the hemorrhagic syndrome, but also to achieve eradication of the inhibitor.
2026-07-03 | Sequential Use of Recombinant Porcine Factor VIII and Early Emicizumab in Acquired Hemophilia A: A Case Series.
Acquired hemophilia A (AHA) is a rare autoimmune bleeding disorder requiring prompt hemostatic control and sustained prevention of rebleeding. Recombinant porcine factor VIII (rpFVIII, susoctocog alfa) controls acute bleeding, while emicizumab provides prophylaxis. Real-world data on their sequential use are limited. To describe clinical outcomes of three patients with AHA who received rpFVIII for initial hemostasis followed by early emicizumab. This case series describes three adults with AHA who received 200 U/kg rpFVIII for acute bleeding, early emicizumab loading on Days 2-3 followed by weekly maintenance, and individualized prednisolone. FVIII activity and inhibitor titers were measured using an emicizumab-neutralized assay with anti-idiotype antibodies. Single-dose rpFVIII achieved hemostasis within 24 h in all patients. No breakthrough bleeding, thrombosis, or adverse events occurred. Inhibitor titers decreased under immunosuppression. Two patients showed FVIII recovery by Day 49. One patient with persistently low FVIII activity remained stable on emicizumab. Hemostasis was achieved even in one patient with a baseline inhibitor titer of 105.8 BU/mL. Sequential rpFVIII followed by early emicizumab maintained bleeding control until inhibitor reduction and FVIII recovery occurred. This strategy was feasible and safe in these three patients. Larger studies are needed. The authors have confirmed clinical trial registration is not needed for this submission.
2026-06-15 | Management of Breakthrough Bleeding During Emicizumab Prophylaxis in Acquired Haemophilia A: Data From the GTH-AHA-EMI Study.
The GTH-AHA-EMI study showed that emicizumab reduces bleeding in patients with acquired haemophilia A (AHA). However, 22 clinically relevant new bleeds (CRNB) occurred in 14 of the 47 study patients, most of which required haemostatic treatment. To describe characteristics, treatment, and outcome of CRNB that occurred during the 12 weeks of haemostatic prophylaxis with emicizumab. Data were extracted from the GTH-AHA-EMI study data base. Further information was collected retrospectively using a standardized questionnaire answered by study investigators. Of the 22 CRNB, 9 and 13 were classified as major and non-major, respectively. 15 bleeds occurred spontaneously, and 20 bleed required treatment. Recombinant factor VIIa was used for treatment in 16 of 20 treated bleeds, recombinant porcine factor VIII was used in three events. Eight patients were admitted to the hospital because of CRNB; extension of hospitalization was reported in 13 patients; 9 were admitted to an intensive care unit; invasive interventions were required in nine patients. Most bleeds were treated successfully; permanent harm from bleeding was reported in two patients. No thromboembolic events or other adverse events were reported. Although emicizumab reduces bleeding in AHA, breakthrough bleeding can still occur, was often severe and required haemostatic treatment. Haemostatic treatment was safe and usually effective. NCT04188639.
2026-06-01 | APTT dynamics after susoctocog alfa for early diagnostic support in suspected acquired hemophilia A: a case report
Acquired hemophilia A (AHA) requires prompt hemostatic intervention; however, definitive diagnosis may be delayed in resource-limited settings, such as community hospitals, where immediate factor VIII (FVIII) activity and inhibitor assays are unavailable. Susoctocog alfa, a recombinant porcine FVIII, differs from bypassing agents in that its hemostatic effect can be reflected in activated partial thromboplastin time (APTT) measurements.
2026-05-15 | Successful Perioperative Management of Pregnancy-Related Acquired Hemophilia A Using Only Bypassing Agents: A Case Report.
We report a confirmed case of pregnancy-associated acquired hemophilia A identified during preoperative evaluation for cesarean delivery. Although immunosuppressive therapy is generally recommended to eradicate factor VIII inhibitors, urgent delivery was required because of pregnancy-induced hypertension complicated by nephropathy. Under these circumstances, a cesarean delivery was performed without previous immunosuppressive treatment. Intraoperative hemostasis was well controlled, and both maternal and neonatal outcomes were favorable. This report may assist in clinical decision-making when invasive procedures are required in patients with acquired hemophilia A before therapeutic intervention with immunosuppressive therapy can be initiated.
antibodies
2026-09-24 | Teclistamab in relapsed, multi-refractory acquired hemophilia A after failure of anti-CD19 CAR-T cell therapy.
A patient with relapsed acquired hemophilia A (AHA), who previously failed multiple lines of immunosuppressive therapy (IST) including autologous anti-CD19 chimeric antigen receptor (CAR) T cell therapy received teclistamab, a bispecific monoclonal antibody engaging autologous CD3-positive T cells with the B cell maturation antigen (BCMA) on plasma cells and mature B cells. Teclistamab was well tolerated without clinically significant adverse events, except for hypogammaglobulinemia. Prompt and durable remission was observed that lasted for more than one year post treatment. This is the first case of refractory AHA successfully treated with teclistamab, providing a proof-of-concept of plasma cell-directed bispecific antibodies, supporting its further evaluation.
2026-09-07 | ACQUIRED HEMOPHILIA A: CURRENT CONCEPTS IN EPIDEMIOLOGY, PATHOGENESIS, DIAGNOSIS, AND MANAGEMENT IN THE EMICIZUMAB ERA
Acquired hemophilia A (AHA) is a rare autoimmune bleeding disorder caused by neutralizing autoantibodies against factor VIII, most often affecting older adults without a prior bleeding history. This narrative review summarizes current knowledge on its epidemiology, pathogenesis, diagnosis, and management, with special attention to emicizumab. A selective PubMed/MEDLINE search of English-language literature published from 2005 to 2025 was performed, prioritizing international guidelines, reviews, registry studies, and clinically relevant cohort reports. AHA typically presents as a hematologic emergency with soft-tissue and mucosal bleeding, isolated prolongation of activated partial thromboplastin time, low factor VIII activity, and a detectable factor VIII inhibitor. Management requires two parallel goals: rapid bleeding control with bypassing agents or recombinant porcine factor VIII, and inhibitor eradication using individualized immunosuppressive therapy. Although remission rates of 70–80% are achievable, mortality remains significant because of both severe bleeding and treatment-related toxicity in elderly, multimorbid patients. Emerging evidence suggests that emicizumab may reduce bleeding burden, limit exposure to intensive bypass therapy, and support safer treatment strategies in selected cases. Earlier recognition, standardized diagnostic pathways, and careful integration of emicizumab may improve outcomes in AHA.
2026-09-04 | Acquired hemophilia A: an updated narrative review
Acquired hemophilia A (AHA) is a rare autoimmune bleeding disorder caused by neutralizing autoantibodies against coagulation factor VIII (FVIII). It usually develops in older adults or during the postpartum period and often presents with new extensive subcutaneous, soft-tissue, muscular, mucosal, or internal bleeding in a person without a previous bleeding history. Diagnostic delay and treatment-related infection remain important causes of avoidable morbidity and mortality. This narrative review integrates international recommendations, registry data, prospective studies, and contemporary real-world evidence published through June 2026. A structured diagnostic pathway begins with recognition of an isolated prolonged activated partial thromboplastin time, exclusion of anticoagulant and pre-analytical effects, an immediate and incubated mixing study, measurement of FVIII activity, and confirmation of a FVIII inhibitor. Acute clinically significant bleeding requires prompt treatment with recombinant activated factor VII, activated prothrombin complex concentrate, or recombinant porcine FVIII; drug selection should reflect bleeding site, thrombosis risk, access, and monitoring capacity. Emicizumab, a subcutaneous bispecific FVIIIa-mimetic antibody, has emerged as effective bleed-prevention therapy while inhibitor eradication is pending. Prospective and real-world studies show substantial reductions in recurrent bleeding and may permit de-escalation or temporary postponement of intensive immunosuppression in selected frail patients. Nevertheless, emicizumab is not an acute rescue agent and does not eradicate the inhibitor. Immunosuppressive therapy therefore remains necessary for immunological remission in most patients, but its intensity should be individualized according to FVIII activity, inhibitor titer, frailty, infection, malignancy, and competing treatment risks. Laboratory monitoring during emicizumab exposure requires assay-specific planning. Modern AHA care should integrate rapid hemostatic control, early bleed prevention, and risk-adapted inhibitor eradication rather than applying a uniform treatment sequence. Clear laboratory communication, explicit definitions of remission, and coordinated follow-up at an experienced hemophilia center are essential to reduce both bleeding-related and treatment-related harm.
2026-08-27 | Acquired hemophilia A: an illustrated review based on the French National Guidelines.
Acquired hemophilia A is a rare but potentially life-threatening autoimmune bleeding disorder caused by the sudden development of neutralizing autoantibodies against factor VIII (FVIII), predominantly affecting older adults. Because of the risk of severe bleeding and excess mortality, prompt hospitalization and immediate management are essential to avoid diagnostic and therapeutic delays. Diagnosis relies on the association of an isolated prolonged activated partial thromboplastin time, reduced FVIII activity, and detection of a FVIII inhibitor quantified using the Bethesda or Nijmegen assay. Management has 2 complementary objectives. First, hemostatic therapy combines preventive measures with treatment of acute bleeding episodes, using bypassing agents (recombinant activated FVIII or activated prothrombin complex concentrate) or recombinant porcine factor VIII as first-line options. More recently, prophylaxis with emicizumab has emerged as a promising strategy to reduce recurrent bleeding, with early clinical data suggesting favorable efficacy and safety. Second, inhibitor eradication relies on immunosuppressive therapy, typically corticosteroids alone or in combination with agents such as cyclophosphamide or rituximab, guided by baseline FVIII activity and inhibitor titer. Close and prolonged follow-up is mandatory, combining clinical assessment of bleeding control, recurrence risk, and treatment toxicity, with laboratory monitoring of hemoglobin, factor VIII activity, von Willebrand factor levels, and inhibitor titers. Surveillance should be maintained for at least 2 years after complete remission.
2026-08-17 | Acquired haemophilia A associated with prostate cancer managed with recombinant activated factor VII and emicizumab.
Acquired haemophilia A (AHA) is a rare autoimmune bleeding disorder caused by neutralising antibodies against factor VIII. We describe an older man with prostate cancer on active surveillance who presented with spontaneous ecchymoses, progressive anaemia and isolated prolongation of activated partial thromboplastin time. Factor VIII activity was severely reduced, and mixing studies and Bethesda assay confirmed a high-titre factor VIII inhibitor. He achieved initial haemostatic control with recombinant-activated factor VII and was transitioned to emicizumab using an accelerated AHA regimen. No corticosteroids were given inpatient. Emicizumab was used for haemostatic prophylaxis while outpatient once-weekly rituximab was planned for inhibitor eradication. This case highlights early recognition, evaluation for associated malignancy and use of emicizumab as prophylaxis that may allow individualised immunosuppression in selected older patients.
cell therapies
2026-08-12 | Successful management of acquired hemophilia A with life-threatening bleeding and MRSA bacteremia in a hemodialysis patient: importance of a multimodal approach
Abstract Background Acquired hemophilia A (AHA) is a rare and fatal bleeding disorder. AHA in patients undergoing hemodialysis (HD) often leads to impaired hemostasis, necessitating temporary catheters that increase the risk of catheter-related infection. This complication hinders the use of immunosuppressive therapy, often resulting in treatment failure. We herein report the case of AHA in a patient undergoing HD with life-threatening bleeding and MRSA bacteremia, which was successfully managed with a multimodal approach. Case presentation A 64-year-old Japanese man had undergone HD owing to diabetic nephropathy and was admitted to our hospital with a massive hematoma in the left iliopsoas muscle and poor hemostasis at the vascular access site. Hemoglobin (Hb) had dropped to 5.0 g/dL despite daily blood transfusions, and activated partial thromboplastin time was alone prolonged around 60.0 s. Transcatheter arterial embolization (TAE) was performed owing to difficulty in hemostasis. After the diagnosis of AHA was made, 60 mg/day of prednisolone and bypassing agents were introduced. Additional plasma exchange (PE) was performed and rituximab was also administered. Factor VIII (FVIII) inhibitor decreased from 91.0 to 32.0 Bethesda Units (B.U)/mL, and hemostasis was achieved temporarily. Despite a decreasing trend, the FVIII inhibitor titer persisted at a high range. Hb decreased to 5.7 g/dL, and blood transfusions were needed again. Thus, a second TAE and a third PE were performed. After that, FVIII inhibitor improved to 7.0 B.U/mL, and hemostasis was fully achieved. Notably, a temporary dialysis catheter led to methicillin-resistant Staphylococcus aureus (MRSA) bacteremia, necessitating careful PSL tapering. At 6 months after discharge, the patient had not experienced any relapse. Conclusions AHA in patients undergoing HD often leads to difficulty in hemostasis during HD, necessitating temporary catheters that almost induce catheter-related infection. This complication hinders the use of immunosuppressive therapy, sometimes resulting in treatment failure. Given the specific clinical setting of AHA in patients undergoing HD, achieving rapid bleeding control and preparing for impending infections are paramount, which necessitates a well-designed multimodal approach including immunosuppressive therapy and PP (plasmapheresis). This instructive case offers a potential framework for managing similar high-risk patients.
2026-03-25 | Hemorrhagic Shock and Massive Abdominal Wall Hematoma After Cesarean Section in a Patient with Peripartum Acquired Hemophilia A:A Case Report.
Acquired Hemophilia A (AHA), a rare bleeding disorder caused by autoimmune suppression of coagulation factor VIII(FVIII), has a low incidence in perinatal women but carries significant risks of severe hemorrhage. The lack of consensus guidelines and limited clinical data from developing countries underscore the importance of this case report. Consequently, this report informs clinical practice and expands the evidence base for the treatment of AHA. This case describes an extensive abdominal wall hematoma and hemorrhagic shock following a cesarean section in a patient. The condition was successfully managed through comprehensive interventions, including shock resuscitation, endovascular embolization, pharmacological hemostatic therapy, removal of circulating immune complexes, and immunosuppressive therapy. AHA usually causes acute bleeding, and early identification and removal of acquired inhibitors are the main treatment methods. In such cases, endovascular embolization is an effective procedure to control bleeding.
2025-12-22 | Laparoscopic Cholecystectomy for Acute Cholecystitis in a Patient with Acquired Hemophilia A: A Case Report of Perioperative Hemostatic Management with Plasma Exchange.
Acquired hemophilia A (AHA) is a rare but potentially life-threatening bleeding disorder caused by autoantibodies against coagulation factor VIII (FVIII). Surgery in patients with AHA is challenging because of the substantial risk of severe perioperative hemorrhage. However, no consensus has been reached on the optimal perioperative hemostatic strategies, especially for urgent surgical settings that require rapid correction of coagulation function, because of the rarity of this condition. A 79-year-old woman was diagnosed with AHA and received immunosuppressive therapy (prednisolone and cyclophosphamide) and hemostatic treatment (activated prothrombin complex concentrate). She developed acute cholecystitis on day 23. However, surgery was initially contraindicated due to inadequate coagulation control, persistently prolonged activated partial thromboplastin time, low FVIII activity, and high FVIII inhibitor titer. Antibiotic therapy was initiated, and endoscopic nasobiliary gallbladder drainage was attempted on day 26. However, the procedure was unsuccessful. The worsening abdominal pain on day 27 prompted further interventions. Plasma exchange (PE) was performed to rapidly reduce the FVIII inhibitor titers and correct the coagulation status before laparoscopic cholecystectomy. The coagulation parameters markedly improved after 3 PE sessions, as evidenced by the shortened activated partial thromboplastin time, increased FVIII activity, and significant reduction in FVIII inhibitor titers. This enabled a safe laparoscopic cholecystectomy with minimal intraoperative blood loss on day 30. No additional PE was required, and the patient was discharged uneventfully on POD 16. The FVIII inhibitor was eliminated within 2 months, and immunosuppressive therapy was discontinued 4 months after surgery. The patient has been in remission to date. This case highlights the potential utility of PE as a bridging strategy to achieve rapid hemostatic correction in patients with AHA requiring urgent surgery, especially those with high-titer FVIII inhibitors. Immunosuppressive therapy and bypassing agents remain the cornerstones of AHA management. However, PE may be an effective adjunct treatment option for refractory cases or in time-constrained settings. This report provides valuable insights into individualized multidisciplinary approaches that may facilitate safe surgical intervention in patients with AHA.
2025-03-08 | Anti-CD19 CAR-T cell therapy for acquired hemophilia A
Acquired hemophilia A (AHA) is a rare autoimmune disorder caused by development of antibodies against clotting factor VIII (FVIII). It is characterized by severe spontaneous bleeding and prolonged bleeding after injury, often life-threatening. The therapeutic approach includes hemostatic medication (bypassing agents and recombinant porcine FVIII) to stop acute bleeding, and immunosuppressive therapy (IST) to eradicate autoantibody formation and induce remission [ 1 ]. Recently, the bispecific antibody emicizumab was introduced to prevent bleeding until remission of AHA [ 2 ]. Approximately 60–80% of patients reach complete remission (CR) over a variable period of weeks to months with established IST regimens. However, resistance to IST can pose a significant clinical challenge, as bleeding symptoms often persist, leading to continued need for hemostatic medications, intractable breakthrough bleeding, and an increased risk of death.
2025-03-04 | [Post-traumatic acquired hemophilia A: a case report and literature review].
Acquired Hemophilia A is an acquired bleeding disorder characterized by reduced FⅧ activity due to the presence of autoantibodies against anticoagulant factor Ⅷ in the circulation. Laboratory tests are typically characterized by prolonged isolated activated partial thromboplastin time (APTT). Clinically, it often manifests as severe bleeding, and 50% of AHA patients can identify the cause. This article reports on a patient with post-traumatic AHA who rapidly improved after antibody removal and bypass replacement therapy, followed by wound healing following surgical intervention. A review of relevant literature is also conducted to enhance clinicians' awareness of AHA, which presents with normal coagulation initially and gradually develops into prolonged APTT accompanied by bleeding manifestations, aiming for early diagnosis and timely treatment.
other
2026-07-27 | High Prevalence of Preexisting Neutralizing Antibodies Against Adeno-Associated Virus Capsids in Mongolian People with Hemophilia.
Adeno-associated virus (AAV) vector-mediated gene therapy for hemophilia offers the potential for sustained therapeutic benefit after a single administration and is particularly attractive in regions with limited access to standard therapies. However, the prevalence of anti-AAV neutralizing antibodies (NAbs), which can impair therapeutic efficacy, varies geographically and remains poorly characterized in Mongolia. Here, we evaluated the seroprevalence of NAbs against clinically relevant AAV serotypes in Mongolia. NAbs against AAV3B, AAV5, and AAV8 were assessed in serum samples from 23 healthy volunteers and 52 people with hemophilia (PwH) using a validated cell-based transduction inhibition assay. A high seroprevalence of anti-AAV NAbs was observed across all three serotypes in both healthy volunteers (69.6%-87.0%) and PwH (78.9%-84.6%), with no significant differences between groups. NAbs were detected across all age groups, including early childhood, and frequently exhibited neutralization against multiple AAV serotypes, which was associated with higher NAb titers. Taken together, anti-AAV NAbs are highly prevalent and acquired early in life in the Mongolian population, with multiserotype neutralization patterns. These findings identify a substantial population-specific barrier to AAV-mediated gene therapy and highlight the need for alternative therapeutic strategies beyond AAV-based platforms to overcome immunological constraints in this setting.
2024-09-28 | Biological Barriers for Drug Delivery and Development of Innovative Therapeutic Approaches in HIV, Pancreatic Cancer, and Hemophilia A/B.
Biological barriers remain a major obstacle for the development of innovative therapeutics. Depending on a disease's pathophysiology, the involved tissues, cell populations, and cellular components, drugs often have to overcome several biological barriers to reach their target cells and become effective in a specific cellular compartment. Human biological barriers are incredibly diverse and include multiple layers of protection and obstruction. Importantly, biological barriers are not only found at the organ/tissue level, but also include cellular structures such as the outer plasma membrane, the endolysosomal machinery, and the nuclear envelope. Nowadays, clinicians have access to a broad arsenal of therapeutics ranging from chemically synthesized small molecules, biologicals including recombinant proteins (such as monoclonal antibodies and hormones), nucleic-acid-based therapeutics, and antibody-drug conjugates (ADCs), to modern viral-vector-mediated gene therapy. In the past decade, the therapeutic landscape has been changing rapidly, giving rise to a multitude of innovative therapy approaches. In 2018, the FDA approval of patisiran paved the way for small interfering RNAs (siRNAs) to become a novel class of nucleic-acid-based therapeutics, which-upon effective drug delivery to their target cells-allow to elegantly regulate the post-transcriptional gene expression. The recent approvals of valoctocogene roxaparvovec and etranacogene dezaparvovec for the treatment of hemophilia A and B, respectively, mark the breakthrough of viral-vector-based gene therapy as a new tool to cure disease. A multitude of highly innovative medicines and drug delivery methods including mRNA-based cancer vaccines and exosome-targeted therapy is on the verge of entering the market and changing the treatment landscape for a broad range of conditions. In this review, we provide insights into three different disease entities, which are clinically, scientifically, and socioeconomically impactful and have given rise to many technological advancements: acquired immunodeficiency syndrome (AIDS) as a predominant infectious disease, pancreatic carcinoma as one of the most lethal solid cancers, and hemophilia A/B as a hereditary genetic disorder. Our primary objective is to highlight the overarching principles of biological barriers that can be identified across different disease areas. Our second goal is to showcase which therapeutic approaches designed to cross disease-specific biological barriers have been promising in effectively treating disease. In this context, we will exemplify how the right selection of the drug category and delivery vehicle, mode of administration, and therapeutic target(s) can help overcome various biological barriers to prevent, treat, and cure disease.
2024-03-06 | A CROSS-SECTIONAL STUDY ON THE PREVALENCE OF HEMOPHILIA IN DISTRICT LARKANA
An inherited bleeding problem is hemophilia. Recombinant clotting factor VIII or factor IX and immunosuppressive drugs are used to treat hemophilia A or B to stop the development of alloantibodies and inhibitors. Treatment of hemophilia is a problem due to the formation of inhibitors to these factors. Patients with inhibitors are treated with activated recombinant factor VII and plasma-derived activated prothrombin complex concentrate. Treatment differs depending on the circumstance since bleeding is more likely to occur in cases of pregnancy, surgery, and cancer. The major topic of this study was to assess healthy persons' awareness of hemophilia and their familiarity with this condition from birth. 30 people from rural Sindh participated in a cross-sectional, random study. All participants were asked regular questions about their awareness of the illness, and SPSS software was used to analyze the data. There is currently no long-term or permanent treatment for hemophilia. Hemophilia may be temporarily cured by factor replacement. The direction of gene therapy or stem cell treatment, both of which are under development, may lead to a permanent cure. Previous research has shown that gene therapy seldom succeeds in curing patients for many months without the requirement for recombinant factor replenishment. To obtain a long-lasting and permanent cure for hemophilia, more adjustments to the treatment plan are necessary.
2023-12-15 | HEMOPHILIA: DIAGNOSIS AND INNOVATIVE MANAGEMENT.
Hemophilia is an acquired,X-linked,passive disorder caused by an insufficiency of utilitarian plasma clotting factor VIII (FVIII). In a critical number of cases, the disorder results from a novo mutation. It rarely manifests as an acquired autoimmune process.Research facility thinks about for suspected hemophilia include a total blood cell tally,coagulation ponders, and an FVIII assay. In patients with an established diagnosis of hemophilia, periodic research facility evaluations include screening for the presence of FVIII inhibitors and screening for transfusion-related or transmissible illnesses such as hepatitis and HIV contamination. Estimation of FVIII levels is critical for observing FVIII substitution treatment. Treatment of hemophilia includes prophylaxis, treatment of bleeding episodes, and induction of immune tolerance.Intended for the treatment and rehabilitation of the patients who are taking factor inhibitors and patients have hemophilic synovitis. Treatment for hemophiliacs should ideally be provided by a Hemophilia Day Care center.We discuss innovative management for the prevention of hemophilia through gene therapy,non-replacement therapy,EHL recombinant concentration,etc.we discuss the data from our studies and emerging results from other gene therapy trials in both hemophilia A and B. This analysis will provide evidence and information on the feasibility and data quality/completeness of the hemophilia database to assess the impact of innovative management on hemophilia outcomes in developing countries.We used a statistical method to analyze the data of adult and pediatric patients who come to hemophilia day care center for taking treatment.The data analysis was performed by the data collected monthly at the hemophilia day care center.
2022-12-15 | Acute-type acquired hemophilia A after COVID-19 mRNA vaccine administration: A new disease entity?
Acquired hemophilia A (AHA) is a rare autoimmune bleeding disorder. Various autoimmune diseases, including AHA, have been reported to occur after the administration of mRNA COVID-19 vaccines. However, the characteristics of these AHA cases remain unclear. We report a case in which AHA arose in a young patient after the administration of an mRNA COVID-19 vaccine, but improved rapidly. The patient's factor VIII (FVIII) inhibitor titer spontaneously decreased to less than half of that seen at diagnosis. One week after the initial immunosuppressive therapy, the FVIII inhibitor had disappeared. Our case suggests that AHA that arises in young patients after COVID-19 vaccination may resolve spontaneously, and the levels of FVIII inhibitors may decrease more rapidly in such cases than in idiopathic AHA. Unlike for immune thrombocytopenic purpura (ITP), no acute type of AHA has been recognized. This case suggests that just as there is an acute type of ITP that develops in children/after vaccination, there may be an acute type of AHA that arises in young patients that receive mRNA COVID-19 vaccines.
small molecules
2026-07-11 | Prepartum Acquired Hemophilia A: Managing a Double Challenge for Mother and Child.
Acquired haemophilia A (AHA) during pregnancy is exceptionally rare and poses significant risks to both mother and fetus, including maternal hemorrhage and neonatal bleeding due to transplacental transfer of factor VIII (FVIII) inhibitors. We report four cases of antenatally diagnosed AHA to provide insights into management and outcomes. All patients received corticosteroids during pregnancy, with individualized peripartum haemostatic strategies using bypassing agents when indicated. Transplacental FVIII inhibitor transfer occurred in three neonates, leading to transient low FVIII levels; only one mild bleeding event was observed, and all infants achieved spontaneous remission within weeks. Postpartum escalation of immunosuppressive therapy, including rituximab, was required in selected mothers to achieve remission. Our series highlights the critical importance of prepartum diagnosis, allowing optimized maternal haemostatic management, avoidance of traumatic delivery, and structured neonatal surveillance to prevent severe bleeding complications.
2026-02-02 | Direct oral anticoagulant interference and removal in the factor VIII inhibitor assay.
Direct oral anticoagulants (DOACs) interfere with clot-based assays, including factor (F)VIII testing and the Nijmegen-Bethesda assay, potentially leading to false-positive results for FVIII inhibitors. Misinterpretation of these results carries serious clinical consequences. Activated charcoal-based products, such as DOAC Remove, may restore assay accuracy, but data supporting their use in FVIII inhibitor assays are limited. In this study, we aim to determine DOAC interference in FVIII inhibitor testing and evaluate effectivity of DOAC removal to restore assay reliability. Normal pooled plasma was spiked with therapeutic and supratherapeutic concentrations of apixaban, edoxaban, rivaroxaban, and dabigatran. Plasma pools from persons with acquired hemophilia A were spiked with DOACs and retested with and without DOAC removal treatment to evaluate workflow performance. FVIII inhibitor activity was measured with and without activated charcoal-based DOAC removal to establish DOAC interference and removal efficacy. Spiking experiments with DOACs caused concentration-dependent false-positive FVIII inhibitor results (>0.6 Nijmegen Bethesda Units/mL), with dabigatran showing the strongest interference and apixaban the weakest. DOAC removal substantially reduced or eliminated interference across all drugs. Post-removal FVIII inhibitor values closely matched baseline concentrations in both spiked normal pooled plasma and pooled patient plasma, with most results within ±20% of the assay variability. DOACs significantly interfere with FVIII inhibitor assays, potentially causing clinically significant false-positive results. Activated charcoal-based DOAC removal treatment provides a practical solution to restore assay reliability. These findings support the integration of DOAC removal into anti-FVIII testing protocols for patients on anticoagulant therapy.
2026-02-01 | Diagnostic Challenges in Acquired Hemophilia A with Concomitant Oral Anticoagulant Use: A Case Series Analysis
Introduction Acquired hemophilia A (AHA) is an uncommon autoimmune bleeding disorder caused by inhibitory autoantibodies directed against coagulation factor VIII (FVIII). Laboratory monitoring of AHA involves serial inhibitor assays to assess treatment response and detect relapse [ 1 ]. The Bethesda assay and its Nijmegen-modified variant quantify residual FVIII activity after incubation of normal plasma with patient plasma, using either a one-stage clotting assay (OSCA) or a chromogenic substrate assay (CSA) [ 2 ]. Both assay formats, however, are susceptible to analytical interference by direct oral anticoagulants (DOACs). In particular, undetected direct factor Xa inhibitors (DFXaIs) may lead to falsely elevated Bethesda titers, potentially misinterpreted as persistent FVIII inhibitors despite clinical remission [ 3 ]. Method Two elderly female patients, aged 86 and 87 years, both with previously treated AHA and confirmed eradication of FVIII autoantibodies, presented during routine follow-up with borderline positive Nijmegen-modified Bethesda assay results (0.7 and 0.8 BU/mL; reference<0.5 BU/mL). Neither patient was under immunosuppressive therapy. Both received apixaban 2.5 mg twice daily—one for secondary prevention after cardioembolic stroke, the other for non-valvular atrial fibrillation. Laboratory testing revealed normal haemostatic screening tests. Liver function tests were within normal limits. Estimated glomerular filtration rate (eGFR) was consistent with moderate-to-severe chronic kidney disease. Haemostatic monitoring included FVIII activity measurement using both OSCA and CSA methods, von Willebrand factor (vWF) activity and antigen, anti-FVIII antibody detection by ELISA, and FVIII inhibitor quantification using the Nijmegen-modified Bethesda assay after heat inactivation. To evaluate possible interference from DOACs, plasma samples were pretreated with DOAC-Remove® and the Nijmegen-modified Bethesda assay was repeated. Results After pretreatment with DOAC-Remove®, FVIII inhibitors were no longer detectable ([ Fig. 1 ]). Apixaban concentrations dropped below the analytical detection limit (<20 ng/mL), confirming effective DOAC removal. Positive control samples containing low-titer FVIII inhibitors demonstrated that DOAC-Remove® treatment did not inactivate FVIII autoantibodies, confirming assay validity. Fig. 1 Laboratory results in patients with AHA before and after DOAC-Remove® Conclusion Accurate laboratory assessment is essential for the diagnosis and follow-up of AHA. False-positive FVIII inhibitor results due to interference from DFXaIs can lead to misinterpretation of disease persistence and inappropriate clinical management. Anti-FVIII ELISA testing may serve as a complementary approach when DFXaI interference is suspected, but its limited specificity must be considered. Pretreatment of plasma samples with activated charcoal-based adsorbents such as DOAC-Remove® or DOAC-Stop® offers a simple and effective method to eliminate DFXaI interference in Nijmegen-modified Bethesda assays, thereby enhancing diagnostic reliability in AHA monitoring. Publication History Article published online: 17 February 2026 © 2026. Thieme. All rights reserved. Georg Thieme Verlag KG Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany
2025-11-07 | Acquired Factor VIII (FVIII) Deficiency: A Case of Idiopathic Hemorrhage.
We report the case of a 34-year-old female with no prior medical history or known bleeding disorders who presented with a large, spontaneous right arm hematoma developing gradually over 10 days, without preceding trauma. She also had multiple ecchymoses and a history of a right calf hematoma three months earlier, initially misdiagnosed and managed as deep venous thrombosis and later as muscle cramp. Laboratory evaluation revealed anemia (hemoglobin: 9.9 g/dL) and a markedly prolonged activated partial thromboplastin time (aPTT) that failed to correct with mixing studies. Factor VIII activity was severely reduced at 4%, with an inhibitor titer of 3.1 Bethesda units, confirming acquired hemophilia A. Imaging demonstrated an intramuscular hematoma within the biceps. The patient was treated with high-dose intravenous methylprednisolone for three days, a single dose of cyclophosphamide, and transitioned to oral prednisolone and azathioprine. Within 24 hours, her aPTT improved to near-normal, and at one-month follow-up, she demonstrated complete resolution of symptoms, normalized FVIII activity, and no recurrence. This case underscores the importance of prompt recognition and combined laboratory, imaging, and clinical assessment in diagnosing acquired hemophilia, particularly in atypical presentations without mucocutaneous bleeding. Early targeted immunosuppressive therapy can result in rapid inhibitor eradication and favorable outcomes.
2025-08-26 | P80 | Early rituximab in acquired haemophilia A: two cases report
Background: Acquired hemophilia A (AHA) is a rare event caused by the development of autoantibodies against factor VIII protein (FVIII). Guidelines recommend rituximab or cytotoxic agents as second-line therapy after 3-4 weeks of corticosteroids to eradicate FVIII inhibitor. We present two case reports of early rituximab use in AHA patients.Case 1: A man with myelomonocytic leukemia presented with widespread hematomas. Lab results showed anemia, prolonged aPTT, FVIII activity 0%, and an inhibitor level of 1.9 BU. Initial treatment with Methylprednisolone, APCC and rVIIa had limited response. Early rituximab therapy (375 mg/m2 weekly for 4 weeks) led to progressive hematoma resolution and eliminated the need for transfusions. After 4 weeks, aPTT was 35s, FVIII activity increased to 62%, and the inhibitor level dropped to 0.4 BU. Case 2: A man with metastatic gastric cancer in chemotherapy presented with left gluteal and abdominal swelling, severe anemia, and prolonged aPTT, reduced FVIII levels and the presence of FVIII inhibitor. CT scan showed the presence of muscular hematomas requiring embolization of the left gluteal and superficial left circumflex iliac arteries. Methylprednisolone and rVIIa were initiated with stability for two weeks. New hematomas prompted rituximab therapy, resulting in hematoma resolution, clinical improvement, normalizing aPTT, FVIII activity with FVIII inhibitor complete eradication.Conclusions: Early rituximab use, contrary to guidelines, effectively restored FVIII levels, reduced inhibitors, and resolved hemorrhagic symptoms in AHA patients.
proteins
2026-07-17 | Acquired hemophilia a induced by clopidogrel
Introduction . Dual antiplatelet therapy (DATT) with aspirin and a platelet P2Y12 receptor inhibitor is one of the main components of treatment and secondary prevention in patients undergoing percutaneous coronary intervention in acute myocardial infarction. Among the side effects of DATT are hemorrhagic complications caused by the antiplatelet effect of the drugs. Less is known about hemorrhagic complications caused by coagulation disorders when taking clopidogrel. Aim : to present a clinical case of acquired hemophilia A, which occurred in a patient as a result of taking clopidogrel. Main findings . A 68-year-old patient received clopidogrel as part of DATT after percutaneous coronary intervention. One month later, he developed a pronounced hemorrhagic syndrome caused by the appearance of antibodies to coagulation factor VIII (FVIII:C 1.5 %, factor VIII inhibitor 61 BU). The elimination of clopidogrel, hemostatic therapy with eptacog alpha (activated) and immunosuppressive therapy with prednisone, cyclophosphamide and rituximab allowed not only to stop the hemorrhagic syndrome, but also to achieve eradication of the inhibitor.
2026-07-03 | Sequential Use of Recombinant Porcine Factor VIII and Early Emicizumab in Acquired Hemophilia A: A Case Series.
Acquired hemophilia A (AHA) is a rare autoimmune bleeding disorder requiring prompt hemostatic control and sustained prevention of rebleeding. Recombinant porcine factor VIII (rpFVIII, susoctocog alfa) controls acute bleeding, while emicizumab provides prophylaxis. Real-world data on their sequential use are limited. To describe clinical outcomes of three patients with AHA who received rpFVIII for initial hemostasis followed by early emicizumab. This case series describes three adults with AHA who received 200 U/kg rpFVIII for acute bleeding, early emicizumab loading on Days 2-3 followed by weekly maintenance, and individualized prednisolone. FVIII activity and inhibitor titers were measured using an emicizumab-neutralized assay with anti-idiotype antibodies. Single-dose rpFVIII achieved hemostasis within 24 h in all patients. No breakthrough bleeding, thrombosis, or adverse events occurred. Inhibitor titers decreased under immunosuppression. Two patients showed FVIII recovery by Day 49. One patient with persistently low FVIII activity remained stable on emicizumab. Hemostasis was achieved even in one patient with a baseline inhibitor titer of 105.8 BU/mL. Sequential rpFVIII followed by early emicizumab maintained bleeding control until inhibitor reduction and FVIII recovery occurred. This strategy was feasible and safe in these three patients. Larger studies are needed. The authors have confirmed clinical trial registration is not needed for this submission.
2026-06-15 | Management of Breakthrough Bleeding During Emicizumab Prophylaxis in Acquired Haemophilia A: Data From the GTH-AHA-EMI Study.
The GTH-AHA-EMI study showed that emicizumab reduces bleeding in patients with acquired haemophilia A (AHA). However, 22 clinically relevant new bleeds (CRNB) occurred in 14 of the 47 study patients, most of which required haemostatic treatment. To describe characteristics, treatment, and outcome of CRNB that occurred during the 12 weeks of haemostatic prophylaxis with emicizumab. Data were extracted from the GTH-AHA-EMI study data base. Further information was collected retrospectively using a standardized questionnaire answered by study investigators. Of the 22 CRNB, 9 and 13 were classified as major and non-major, respectively. 15 bleeds occurred spontaneously, and 20 bleed required treatment. Recombinant factor VIIa was used for treatment in 16 of 20 treated bleeds, recombinant porcine factor VIII was used in three events. Eight patients were admitted to the hospital because of CRNB; extension of hospitalization was reported in 13 patients; 9 were admitted to an intensive care unit; invasive interventions were required in nine patients. Most bleeds were treated successfully; permanent harm from bleeding was reported in two patients. No thromboembolic events or other adverse events were reported. Although emicizumab reduces bleeding in AHA, breakthrough bleeding can still occur, was often severe and required haemostatic treatment. Haemostatic treatment was safe and usually effective. NCT04188639.
2026-06-01 | APTT dynamics after susoctocog alfa for early diagnostic support in suspected acquired hemophilia A: a case report
Acquired hemophilia A (AHA) requires prompt hemostatic intervention; however, definitive diagnosis may be delayed in resource-limited settings, such as community hospitals, where immediate factor VIII (FVIII) activity and inhibitor assays are unavailable. Susoctocog alfa, a recombinant porcine FVIII, differs from bypassing agents in that its hemostatic effect can be reflected in activated partial thromboplastin time (APTT) measurements.
2026-05-15 | Successful Perioperative Management of Pregnancy-Related Acquired Hemophilia A Using Only Bypassing Agents: A Case Report.
We report a confirmed case of pregnancy-associated acquired hemophilia A identified during preoperative evaluation for cesarean delivery. Although immunosuppressive therapy is generally recommended to eradicate factor VIII inhibitors, urgent delivery was required because of pregnancy-induced hypertension complicated by nephropathy. Under these circumstances, a cesarean delivery was performed without previous immunosuppressive treatment. Intraoperative hemostasis was well controlled, and both maternal and neonatal outcomes were favorable. This report may assist in clinical decision-making when invasive procedures are required in patients with acquired hemophilia A before therapeutic intervention with immunosuppressive therapy can be initiated.
antibodies
2026-09-24 | Teclistamab in relapsed, multi-refractory acquired hemophilia A after failure of anti-CD19 CAR-T cell therapy.
A patient with relapsed acquired hemophilia A (AHA), who previously failed multiple lines of immunosuppressive therapy (IST) including autologous anti-CD19 chimeric antigen receptor (CAR) T cell therapy received teclistamab, a bispecific monoclonal antibody engaging autologous CD3-positive T cells with the B cell maturation antigen (BCMA) on plasma cells and mature B cells. Teclistamab was well tolerated without clinically significant adverse events, except for hypogammaglobulinemia. Prompt and durable remission was observed that lasted for more than one year post treatment. This is the first case of refractory AHA successfully treated with teclistamab, providing a proof-of-concept of plasma cell-directed bispecific antibodies, supporting its further evaluation.
2026-09-07 | ACQUIRED HEMOPHILIA A: CURRENT CONCEPTS IN EPIDEMIOLOGY, PATHOGENESIS, DIAGNOSIS, AND MANAGEMENT IN THE EMICIZUMAB ERA
Acquired hemophilia A (AHA) is a rare autoimmune bleeding disorder caused by neutralizing autoantibodies against factor VIII, most often affecting older adults without a prior bleeding history. This narrative review summarizes current knowledge on its epidemiology, pathogenesis, diagnosis, and management, with special attention to emicizumab. A selective PubMed/MEDLINE search of English-language literature published from 2005 to 2025 was performed, prioritizing international guidelines, reviews, registry studies, and clinically relevant cohort reports. AHA typically presents as a hematologic emergency with soft-tissue and mucosal bleeding, isolated prolongation of activated partial thromboplastin time, low factor VIII activity, and a detectable factor VIII inhibitor. Management requires two parallel goals: rapid bleeding control with bypassing agents or recombinant porcine factor VIII, and inhibitor eradication using individualized immunosuppressive therapy. Although remission rates of 70–80% are achievable, mortality remains significant because of both severe bleeding and treatment-related toxicity in elderly, multimorbid patients. Emerging evidence suggests that emicizumab may reduce bleeding burden, limit exposure to intensive bypass therapy, and support safer treatment strategies in selected cases. Earlier recognition, standardized diagnostic pathways, and careful integration of emicizumab may improve outcomes in AHA.
2026-09-04 | Acquired hemophilia A: an updated narrative review
Acquired hemophilia A (AHA) is a rare autoimmune bleeding disorder caused by neutralizing autoantibodies against coagulation factor VIII (FVIII). It usually develops in older adults or during the postpartum period and often presents with new extensive subcutaneous, soft-tissue, muscular, mucosal, or internal bleeding in a person without a previous bleeding history. Diagnostic delay and treatment-related infection remain important causes of avoidable morbidity and mortality. This narrative review integrates international recommendations, registry data, prospective studies, and contemporary real-world evidence published through June 2026. A structured diagnostic pathway begins with recognition of an isolated prolonged activated partial thromboplastin time, exclusion of anticoagulant and pre-analytical effects, an immediate and incubated mixing study, measurement of FVIII activity, and confirmation of a FVIII inhibitor. Acute clinically significant bleeding requires prompt treatment with recombinant activated factor VII, activated prothrombin complex concentrate, or recombinant porcine FVIII; drug selection should reflect bleeding site, thrombosis risk, access, and monitoring capacity. Emicizumab, a subcutaneous bispecific FVIIIa-mimetic antibody, has emerged as effective bleed-prevention therapy while inhibitor eradication is pending. Prospective and real-world studies show substantial reductions in recurrent bleeding and may permit de-escalation or temporary postponement of intensive immunosuppression in selected frail patients. Nevertheless, emicizumab is not an acute rescue agent and does not eradicate the inhibitor. Immunosuppressive therapy therefore remains necessary for immunological remission in most patients, but its intensity should be individualized according to FVIII activity, inhibitor titer, frailty, infection, malignancy, and competing treatment risks. Laboratory monitoring during emicizumab exposure requires assay-specific planning. Modern AHA care should integrate rapid hemostatic control, early bleed prevention, and risk-adapted inhibitor eradication rather than applying a uniform treatment sequence. Clear laboratory communication, explicit definitions of remission, and coordinated follow-up at an experienced hemophilia center are essential to reduce both bleeding-related and treatment-related harm.
2026-08-27 | Acquired hemophilia A: an illustrated review based on the French National Guidelines.
Acquired hemophilia A is a rare but potentially life-threatening autoimmune bleeding disorder caused by the sudden development of neutralizing autoantibodies against factor VIII (FVIII), predominantly affecting older adults. Because of the risk of severe bleeding and excess mortality, prompt hospitalization and immediate management are essential to avoid diagnostic and therapeutic delays. Diagnosis relies on the association of an isolated prolonged activated partial thromboplastin time, reduced FVIII activity, and detection of a FVIII inhibitor quantified using the Bethesda or Nijmegen assay. Management has 2 complementary objectives. First, hemostatic therapy combines preventive measures with treatment of acute bleeding episodes, using bypassing agents (recombinant activated FVIII or activated prothrombin complex concentrate) or recombinant porcine factor VIII as first-line options. More recently, prophylaxis with emicizumab has emerged as a promising strategy to reduce recurrent bleeding, with early clinical data suggesting favorable efficacy and safety. Second, inhibitor eradication relies on immunosuppressive therapy, typically corticosteroids alone or in combination with agents such as cyclophosphamide or rituximab, guided by baseline FVIII activity and inhibitor titer. Close and prolonged follow-up is mandatory, combining clinical assessment of bleeding control, recurrence risk, and treatment toxicity, with laboratory monitoring of hemoglobin, factor VIII activity, von Willebrand factor levels, and inhibitor titers. Surveillance should be maintained for at least 2 years after complete remission.
2026-08-17 | Acquired haemophilia A associated with prostate cancer managed with recombinant activated factor VII and emicizumab.
Acquired haemophilia A (AHA) is a rare autoimmune bleeding disorder caused by neutralising antibodies against factor VIII. We describe an older man with prostate cancer on active surveillance who presented with spontaneous ecchymoses, progressive anaemia and isolated prolongation of activated partial thromboplastin time. Factor VIII activity was severely reduced, and mixing studies and Bethesda assay confirmed a high-titre factor VIII inhibitor. He achieved initial haemostatic control with recombinant-activated factor VII and was transitioned to emicizumab using an accelerated AHA regimen. No corticosteroids were given inpatient. Emicizumab was used for haemostatic prophylaxis while outpatient once-weekly rituximab was planned for inhibitor eradication. This case highlights early recognition, evaluation for associated malignancy and use of emicizumab as prophylaxis that may allow individualised immunosuppression in selected older patients.
cell therapies
2026-08-12 | Successful management of acquired hemophilia A with life-threatening bleeding and MRSA bacteremia in a hemodialysis patient: importance of a multimodal approach
Abstract Background Acquired hemophilia A (AHA) is a rare and fatal bleeding disorder. AHA in patients undergoing hemodialysis (HD) often leads to impaired hemostasis, necessitating temporary catheters that increase the risk of catheter-related infection. This complication hinders the use of immunosuppressive therapy, often resulting in treatment failure. We herein report the case of AHA in a patient undergoing HD with life-threatening bleeding and MRSA bacteremia, which was successfully managed with a multimodal approach. Case presentation A 64-year-old Japanese man had undergone HD owing to diabetic nephropathy and was admitted to our hospital with a massive hematoma in the left iliopsoas muscle and poor hemostasis at the vascular access site. Hemoglobin (Hb) had dropped to 5.0 g/dL despite daily blood transfusions, and activated partial thromboplastin time was alone prolonged around 60.0 s. Transcatheter arterial embolization (TAE) was performed owing to difficulty in hemostasis. After the diagnosis of AHA was made, 60 mg/day of prednisolone and bypassing agents were introduced. Additional plasma exchange (PE) was performed and rituximab was also administered. Factor VIII (FVIII) inhibitor decreased from 91.0 to 32.0 Bethesda Units (B.U)/mL, and hemostasis was achieved temporarily. Despite a decreasing trend, the FVIII inhibitor titer persisted at a high range. Hb decreased to 5.7 g/dL, and blood transfusions were needed again. Thus, a second TAE and a third PE were performed. After that, FVIII inhibitor improved to 7.0 B.U/mL, and hemostasis was fully achieved. Notably, a temporary dialysis catheter led to methicillin-resistant Staphylococcus aureus (MRSA) bacteremia, necessitating careful PSL tapering. At 6 months after discharge, the patient had not experienced any relapse. Conclusions AHA in patients undergoing HD often leads to difficulty in hemostasis during HD, necessitating temporary catheters that almost induce catheter-related infection. This complication hinders the use of immunosuppressive therapy, sometimes resulting in treatment failure. Given the specific clinical setting of AHA in patients undergoing HD, achieving rapid bleeding control and preparing for impending infections are paramount, which necessitates a well-designed multimodal approach including immunosuppressive therapy and PP (plasmapheresis). This instructive case offers a potential framework for managing similar high-risk patients.
2026-03-25 | Hemorrhagic Shock and Massive Abdominal Wall Hematoma After Cesarean Section in a Patient with Peripartum Acquired Hemophilia A:A Case Report.
Acquired Hemophilia A (AHA), a rare bleeding disorder caused by autoimmune suppression of coagulation factor VIII(FVIII), has a low incidence in perinatal women but carries significant risks of severe hemorrhage. The lack of consensus guidelines and limited clinical data from developing countries underscore the importance of this case report. Consequently, this report informs clinical practice and expands the evidence base for the treatment of AHA. This case describes an extensive abdominal wall hematoma and hemorrhagic shock following a cesarean section in a patient. The condition was successfully managed through comprehensive interventions, including shock resuscitation, endovascular embolization, pharmacological hemostatic therapy, removal of circulating immune complexes, and immunosuppressive therapy. AHA usually causes acute bleeding, and early identification and removal of acquired inhibitors are the main treatment methods. In such cases, endovascular embolization is an effective procedure to control bleeding.
2025-12-22 | Laparoscopic Cholecystectomy for Acute Cholecystitis in a Patient with Acquired Hemophilia A: A Case Report of Perioperative Hemostatic Management with Plasma Exchange.
Acquired hemophilia A (AHA) is a rare but potentially life-threatening bleeding disorder caused by autoantibodies against coagulation factor VIII (FVIII). Surgery in patients with AHA is challenging because of the substantial risk of severe perioperative hemorrhage. However, no consensus has been reached on the optimal perioperative hemostatic strategies, especially for urgent surgical settings that require rapid correction of coagulation function, because of the rarity of this condition. A 79-year-old woman was diagnosed with AHA and received immunosuppressive therapy (prednisolone and cyclophosphamide) and hemostatic treatment (activated prothrombin complex concentrate). She developed acute cholecystitis on day 23. However, surgery was initially contraindicated due to inadequate coagulation control, persistently prolonged activated partial thromboplastin time, low FVIII activity, and high FVIII inhibitor titer. Antibiotic therapy was initiated, and endoscopic nasobiliary gallbladder drainage was attempted on day 26. However, the procedure was unsuccessful. The worsening abdominal pain on day 27 prompted further interventions. Plasma exchange (PE) was performed to rapidly reduce the FVIII inhibitor titers and correct the coagulation status before laparoscopic cholecystectomy. The coagulation parameters markedly improved after 3 PE sessions, as evidenced by the shortened activated partial thromboplastin time, increased FVIII activity, and significant reduction in FVIII inhibitor titers. This enabled a safe laparoscopic cholecystectomy with minimal intraoperative blood loss on day 30. No additional PE was required, and the patient was discharged uneventfully on POD 16. The FVIII inhibitor was eliminated within 2 months, and immunosuppressive therapy was discontinued 4 months after surgery. The patient has been in remission to date. This case highlights the potential utility of PE as a bridging strategy to achieve rapid hemostatic correction in patients with AHA requiring urgent surgery, especially those with high-titer FVIII inhibitors. Immunosuppressive therapy and bypassing agents remain the cornerstones of AHA management. However, PE may be an effective adjunct treatment option for refractory cases or in time-constrained settings. This report provides valuable insights into individualized multidisciplinary approaches that may facilitate safe surgical intervention in patients with AHA.
2025-03-08 | Anti-CD19 CAR-T cell therapy for acquired hemophilia A
Acquired hemophilia A (AHA) is a rare autoimmune disorder caused by development of antibodies against clotting factor VIII (FVIII). It is characterized by severe spontaneous bleeding and prolonged bleeding after injury, often life-threatening. The therapeutic approach includes hemostatic medication (bypassing agents and recombinant porcine FVIII) to stop acute bleeding, and immunosuppressive therapy (IST) to eradicate autoantibody formation and induce remission [ 1 ]. Recently, the bispecific antibody emicizumab was introduced to prevent bleeding until remission of AHA [ 2 ]. Approximately 60–80% of patients reach complete remission (CR) over a variable period of weeks to months with established IST regimens. However, resistance to IST can pose a significant clinical challenge, as bleeding symptoms often persist, leading to continued need for hemostatic medications, intractable breakthrough bleeding, and an increased risk of death.
2025-03-04 | [Post-traumatic acquired hemophilia A: a case report and literature review].
Acquired Hemophilia A is an acquired bleeding disorder characterized by reduced FⅧ activity due to the presence of autoantibodies against anticoagulant factor Ⅷ in the circulation. Laboratory tests are typically characterized by prolonged isolated activated partial thromboplastin time (APTT). Clinically, it often manifests as severe bleeding, and 50% of AHA patients can identify the cause. This article reports on a patient with post-traumatic AHA who rapidly improved after antibody removal and bypass replacement therapy, followed by wound healing following surgical intervention. A review of relevant literature is also conducted to enhance clinicians' awareness of AHA, which presents with normal coagulation initially and gradually develops into prolonged APTT accompanied by bleeding manifestations, aiming for early diagnosis and timely treatment.
other
2026-07-27 | High Prevalence of Preexisting Neutralizing Antibodies Against Adeno-Associated Virus Capsids in Mongolian People with Hemophilia.
Adeno-associated virus (AAV) vector-mediated gene therapy for hemophilia offers the potential for sustained therapeutic benefit after a single administration and is particularly attractive in regions with limited access to standard therapies. However, the prevalence of anti-AAV neutralizing antibodies (NAbs), which can impair therapeutic efficacy, varies geographically and remains poorly characterized in Mongolia. Here, we evaluated the seroprevalence of NAbs against clinically relevant AAV serotypes in Mongolia. NAbs against AAV3B, AAV5, and AAV8 were assessed in serum samples from 23 healthy volunteers and 52 people with hemophilia (PwH) using a validated cell-based transduction inhibition assay. A high seroprevalence of anti-AAV NAbs was observed across all three serotypes in both healthy volunteers (69.6%-87.0%) and PwH (78.9%-84.6%), with no significant differences between groups. NAbs were detected across all age groups, including early childhood, and frequently exhibited neutralization against multiple AAV serotypes, which was associated with higher NAb titers. Taken together, anti-AAV NAbs are highly prevalent and acquired early in life in the Mongolian population, with multiserotype neutralization patterns. These findings identify a substantial population-specific barrier to AAV-mediated gene therapy and highlight the need for alternative therapeutic strategies beyond AAV-based platforms to overcome immunological constraints in this setting.
2024-09-28 | Biological Barriers for Drug Delivery and Development of Innovative Therapeutic Approaches in HIV, Pancreatic Cancer, and Hemophilia A/B.
Biological barriers remain a major obstacle for the development of innovative therapeutics. Depending on a disease's pathophysiology, the involved tissues, cell populations, and cellular components, drugs often have to overcome several biological barriers to reach their target cells and become effective in a specific cellular compartment. Human biological barriers are incredibly diverse and include multiple layers of protection and obstruction. Importantly, biological barriers are not only found at the organ/tissue level, but also include cellular structures such as the outer plasma membrane, the endolysosomal machinery, and the nuclear envelope. Nowadays, clinicians have access to a broad arsenal of therapeutics ranging from chemically synthesized small molecules, biologicals including recombinant proteins (such as monoclonal antibodies and hormones), nucleic-acid-based therapeutics, and antibody-drug conjugates (ADCs), to modern viral-vector-mediated gene therapy. In the past decade, the therapeutic landscape has been changing rapidly, giving rise to a multitude of innovative therapy approaches. In 2018, the FDA approval of patisiran paved the way for small interfering RNAs (siRNAs) to become a novel class of nucleic-acid-based therapeutics, which-upon effective drug delivery to their target cells-allow to elegantly regulate the post-transcriptional gene expression. The recent approvals of valoctocogene roxaparvovec and etranacogene dezaparvovec for the treatment of hemophilia A and B, respectively, mark the breakthrough of viral-vector-based gene therapy as a new tool to cure disease. A multitude of highly innovative medicines and drug delivery methods including mRNA-based cancer vaccines and exosome-targeted therapy is on the verge of entering the market and changing the treatment landscape for a broad range of conditions. In this review, we provide insights into three different disease entities, which are clinically, scientifically, and socioeconomically impactful and have given rise to many technological advancements: acquired immunodeficiency syndrome (AIDS) as a predominant infectious disease, pancreatic carcinoma as one of the most lethal solid cancers, and hemophilia A/B as a hereditary genetic disorder. Our primary objective is to highlight the overarching principles of biological barriers that can be identified across different disease areas. Our second goal is to showcase which therapeutic approaches designed to cross disease-specific biological barriers have been promising in effectively treating disease. In this context, we will exemplify how the right selection of the drug category and delivery vehicle, mode of administration, and therapeutic target(s) can help overcome various biological barriers to prevent, treat, and cure disease.
2024-03-06 | A CROSS-SECTIONAL STUDY ON THE PREVALENCE OF HEMOPHILIA IN DISTRICT LARKANA
An inherited bleeding problem is hemophilia. Recombinant clotting factor VIII or factor IX and immunosuppressive drugs are used to treat hemophilia A or B to stop the development of alloantibodies and inhibitors. Treatment of hemophilia is a problem due to the formation of inhibitors to these factors. Patients with inhibitors are treated with activated recombinant factor VII and plasma-derived activated prothrombin complex concentrate. Treatment differs depending on the circumstance since bleeding is more likely to occur in cases of pregnancy, surgery, and cancer. The major topic of this study was to assess healthy persons' awareness of hemophilia and their familiarity with this condition from birth. 30 people from rural Sindh participated in a cross-sectional, random study. All participants were asked regular questions about their awareness of the illness, and SPSS software was used to analyze the data. There is currently no long-term or permanent treatment for hemophilia. Hemophilia may be temporarily cured by factor replacement. The direction of gene therapy or stem cell treatment, both of which are under development, may lead to a permanent cure. Previous research has shown that gene therapy seldom succeeds in curing patients for many months without the requirement for recombinant factor replenishment. To obtain a long-lasting and permanent cure for hemophilia, more adjustments to the treatment plan are necessary.
2023-12-15 | HEMOPHILIA: DIAGNOSIS AND INNOVATIVE MANAGEMENT.
Hemophilia is an acquired,X-linked,passive disorder caused by an insufficiency of utilitarian plasma clotting factor VIII (FVIII). In a critical number of cases, the disorder results from a novo mutation. It rarely manifests as an acquired autoimmune process.Research facility thinks about for suspected hemophilia include a total blood cell tally,coagulation ponders, and an FVIII assay. In patients with an established diagnosis of hemophilia, periodic research facility evaluations include screening for the presence of FVIII inhibitors and screening for transfusion-related or transmissible illnesses such as hepatitis and HIV contamination. Estimation of FVIII levels is critical for observing FVIII substitution treatment. Treatment of hemophilia includes prophylaxis, treatment of bleeding episodes, and induction of immune tolerance.Intended for the treatment and rehabilitation of the patients who are taking factor inhibitors and patients have hemophilic synovitis. Treatment for hemophiliacs should ideally be provided by a Hemophilia Day Care center.We discuss innovative management for the prevention of hemophilia through gene therapy,non-replacement therapy,EHL recombinant concentration,etc.we discuss the data from our studies and emerging results from other gene therapy trials in both hemophilia A and B. This analysis will provide evidence and information on the feasibility and data quality/completeness of the hemophilia database to assess the impact of innovative management on hemophilia outcomes in developing countries.We used a statistical method to analyze the data of adult and pediatric patients who come to hemophilia day care center for taking treatment.The data analysis was performed by the data collected monthly at the hemophilia day care center.
2022-12-15 | Acute-type acquired hemophilia A after COVID-19 mRNA vaccine administration: A new disease entity?
Acquired hemophilia A (AHA) is a rare autoimmune bleeding disorder. Various autoimmune diseases, including AHA, have been reported to occur after the administration of mRNA COVID-19 vaccines. However, the characteristics of these AHA cases remain unclear. We report a case in which AHA arose in a young patient after the administration of an mRNA COVID-19 vaccine, but improved rapidly. The patient's factor VIII (FVIII) inhibitor titer spontaneously decreased to less than half of that seen at diagnosis. One week after the initial immunosuppressive therapy, the FVIII inhibitor had disappeared. Our case suggests that AHA that arises in young patients after COVID-19 vaccination may resolve spontaneously, and the levels of FVIII inhibitors may decrease more rapidly in such cases than in idiopathic AHA. Unlike for immune thrombocytopenic purpura (ITP), no acute type of AHA has been recognized. This case suggests that just as there is an acute type of ITP that develops in children/after vaccination, there may be an acute type of AHA that arises in young patients that receive mRNA COVID-19 vaccines.
Access all drug discovery papers and probability of success in trials forecasts:
Access all drug discovery papers and probability of success in trials forecasts:
Drug Discovery Landscape
0 orphan drug designations.
0 orphan drug designations.
Let's accelerate rare disease drug discovery
Let's accelerate drug discovery
Get access to Explority AI’s forecasts to outperform average preclinical success rates. Whether you’re expanding your R&D pipeline, evaluating a partnership, or simply have a question — we’d love to hear from you.